%0 Journal Article %T Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France data from the OFSEP database over the period 1996-2017 %+ École des Hautes Études en Santé Publique [EHESP] (EHESP) %+ Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES) %+ Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS) %+ CHU Strasbourg %+ Centre hospitalier universitaire de Nantes (CHU Nantes) %+ Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL) %A Leray, Emmanuelle %A Rollot, F. %A Casey, Romain %A de Seze, J. %A Laplaud, D. A. %A Vukusic, S. %Z Agence Nationale de la Recherche within the framework of the "Investments for the Future" program [ANR-10-COHO-002] %Z Novartis %Z Alergan %Z Sanofi-Genzyme %Z Geneuro %Z Roche %Z Medday %Z Genzyme-Sanofi %Z Roche SAS %Z Merck-Serono %Z French State %Z French ARSEP Foundation %Z Biogen %Z French National Security Agency of Medicines and Health Products %Z EDMUS Foundation %Z Merck Serono %Z Sanofi-Aventis %Z Bayer %Z LFB %Z Teva %Z Genzyme %Z Almiral %< avec comité de lecture %@ 1352-4585 %J Multiple Sclerosis Journal %I SAGE Publications %V 23 %P 709-709 %8 2017 %D 2017 %R 10.26226/morressier.59a3e8b4d462b8028d894343 %Z Life Sciences [q-bio]/Santé publique et épidémiologieJournal articles %G English %L hal-01716027 %U https://univ-rennes.hal.science/hal-01716027 %~ UNIV-ST-ETIENNE %~ HCL %~ UNIV-RENNES1 %~ CNRS %~ UNIV-LYON1 %~ SANTE_PUB_INSERM %~ CHLS %~ STATS-UR1 %~ OFSEP %~ UR1-UFR-SVE %~ UR1-HAL %~ EHESP %~ USPC %~ REPERES %~ METIS-EHESP %~ TEST-UR-CSS %~ UNIV-RENNES %~ UDL %~ UNIV-LYON %~ TEST-HALCNRS %~ ANR %~ UR1-BIO-SA %~ CRNL